Pfizer Inc. (NYSE: PFE) today announced that it has entered into settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd, regarding lawsuits filed in ...

Pfizer has abandoned work on a PD-L1-targeting drug that was being tested in patients with various cancers. | Pfizer has ...

Pfizer inking the last of three settlements to postpone copycats to its transthyretin amyloid cardiomyopathy (ATTR-CM) med ...

BridgeBio Pharma has declined to participate in the National Advertising Division’s (NAD’s) investigation into complaints made by Pfizer, leading the self-regulatory body to refer the case to federal ...

Sept 3 (Reuters) - Pfizer (PFE.N), opens new tab and Moderna (MRNA.O), opens new tab on Wednesday defended their COVID-19 vaccines as having saved millions of lives worldwide, in separate responses to ...

There might be room for two titans in the obesity business, but a third player might have a uniquely marketable option.

Pfizer delivered a significant earnings surprise in its third-quarter results, demonstrating the pharmaceutical giant’s resilience amid a challenging year for its stock performance. The company’s ...

Pfizer's vaccine business cooled off, and it is on its back foot in the GLP-1 race, but don't count the drug giant out.

Pfizer (NYSE: PFE) is one of the world's largest pharmaceutical companies. It has a long history of innovation and success. Add in a lofty 6.6% dividend yield, and dividend investors are likely to ...

Pfizer delivers a 75.81% gross margin and 41.05% EBITDA margin, dramatically outperforming sector medians of 59.35% and 10.40%. Management targets $1.3 billion in net cost savings by 2026, reinforcing ...

Pfizer PFE stock has declined around 3% this week. On Dec. 16, the company announced its financial guidance for 2026, which fell short of investor expectations. Pfizer expects total revenues for 2026 ...